Abstract: Method of determining therapeutic drug antibodies in a sample of bodily fluid of a subject receiving a medication containing a therapeutic drug antibodies against tumor necrosis factor alpha. The method is used in an lateral flow immunochromatographic test wherein the immunochromatographic bridging and binding in the test line comprises the use of an anti-idiotypic scFv fragment or Fab fragment fused to a carrier protein which is not involved in nor plays a role in the inherent or developed immune system. The fusion protein may contain human serum albumin, chicken ovalbumin, human haptoglobin or human alpha-1- antitrypsin. The immunological reaction is therefore not impaired, augmented or interfered by members of the complement system or by autoantibodies such as the rheumatoid factor. This is of particular importance and favorable when determining the concentration of tumor necrosis alpha blockers such as adalimumab or in-fliximab in serum or blood of patients.

Abstract: A method for quantitative determination of bioavailable L-tryptophan in faeces and a method of diagnosis whether a subject is suffering from impaired fructose absorption or from a lack of bioavailable tryptophan. The latter includes the localization of a previously hidden aetiology of decreased blood tryptophan levels and a method of in vitro diagnosis of the aetiology of gastrointestinal (IBD), Crohn's disease, depression symptoms, anxiety, insomnia, sleep disorders, dysphoric disorders. A kit of parts for determining the ratio of free L-tryptophan to blocked glycated tryptophan or fructosyl-tryptophan adduct for immediate treatment of these disorders by providingpatients with appropriate dietary recommendations or an intake of tryptophan that is not blocked or glycated in the acidic environment of the stomach or gastrointestinal tract.

Abstract: A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.

Abstract: A method of diagnosis of histamine intolerance in a person suspected of suffering from histamine intolerance syndrome. Isotope-labeled histamine metabolites, namely imidazole acetic acid and methylimidazole acetic acid are identified and measured in serum, plasma, urine and other bodily fluids following derivatization with a hydrazinoquinoline derivatization agent using the LC-MS/MS technique. The method and analytical technique is very sensitive and allows a safe use of an isotope-labeled oral histamine load as well as time-dependent measurements of the total activity of secreted and membrane-associated DAO enzymes for the sake of a differential diagnosis of histamine intolerance syndrome compared to food allergy, food hypersensitivity or food intolerance.

Abstract: In vitro method for determining the type and severity of a gastrointestinal disorder in a subject suspected of suffering irritable bowel syndrome (IBS), comprising the steps of a) performing an assay method for detecting the presence of ?-tryptase in a fecal sample obtained from said patient; b) measuring the concentration of ?-tryptase in said fecal sample; c) comparing said measured concentration of ?-tryptase to a first predetermined reference value; and d) assessing of said patient by assigning an increased likelihood of suffering irritable bowel syndrome (IBS) when said measured concentration of ?-tryptase is higher than said predetermined reference value, or by assigning a decreased likelihood of suffering irritable bowel syndrome (IBS) when said measured concentration of ?-tryptase is lower than said predetermined reference value.

Abstract: An analyte testing system for quantifying the presence of an analyte in a specimen by immunochromatography. The system comprises a camera test card, depicting a test cassette (10) with an immunochromatography and a handheld processor device (16) comprising a digital camera (16a), a source of light (16b) and a processor (16c), which software and hardware (16c) are configured to make a pose estimation of camera and object and the measures of light in the region of interest of the immunochromatography. The system allows an automatic camera calibration and certification as a scanner for use in point-of-care diagnostics.

Abstract: A composition comprising a monoclonal antibody against bone sialoprotein (BSP) for use in a therapy of cardioprotection in a subject suspected of suffering from fibrosis, whereby a pathological accumulation of collagen and/or the progression of fibrosis are prevented.

Abstract: The disclosure relates to a point-of-care test device for diagnosis and detection of bacterial infections and hidden septic processes in samples of bodily fluids of premature and newborns comprising a quantitative or semi-quantitative lateral flow immunoassay unit adapted for parallel detection of proteins of the S100 family and for several detection of increased amounts of S100A12 and calprotectin in blood, serum, plasma, and saliva.

Abstract: A prosthetic polylactide or collagen-containing scaffold material for treating osseous defects and neogenesis of bone, obtained by printing a scaffold composed of strings of polylactide and porous microstructures which allow passage and ingrowth of bone tissue. A soluble mixture of BSP and/or collagen is provided, and BSP and/or collagen is applied onto the strings and in the pores of the printed body to obtain a prosthetic material which induces tissue-directed ingrowth of bone tissue as well as repair and healing of damaged or diseased bone tissues and lesions. The prosthetic material is osseo-inductive and osseo-conductive. The BSP in the prosthetic scaffold material induces a tissue-directed growth of osseous tissue. No undirectional callous or overgrowing bone and cartilage tissue is observed.

Abstract: A method comprising the steps of: (a) collecting a stool sample with the analyte and transferring a defined amount of stool sample into a prepared vessel having a sieve filter and a predetermined amount of extraction solution; (b) suspending and extracting the stool sample in the extraction solution so that the analyte goes into solution; (c) filtering the extraction solution through the sieve filter and transferring a defined amount of extraction solution to a cellulosic fibrous web having predetermined absorbency; (d) rapid drying of the extraction solution on the cellulose fibrous web at ambient temperature by the capillary action of the fibrous web, wherein the fibrous web with the sample extraction solution represents a storage and transport form stable over days and weeks, on which analyte and digestive enzymes are physically separated from each other; (e) collecting and extracting the analyte from the fibrous web in a predetermined amount of assay buffer; (f) separating the fibrous web from the assay b

Abstract: A method for pre-analytical treatment of a serum or plasma sample from a patient suspected of suffering from oxidative stress, which includes contacting the sample with one or more microcapsules having a gelled alginate core and a semipermeable coating, where the alginate core includes dispersed receptors against an oxidised human parathyroid hormone (PTH) peptide. The semipermeable membrane can be obtained by layer-by-layer deposition of polycationic and polyanionic macromolecules onto the gelled core, following by hardening, crosslinking and co-acervation of the macroionic phases.

Abstract: A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.

Abstract: A method for detecting and quantifying anti-neutrophil-cytoplasmic antibodies (ANCA) in a sample of bodily fluid from a patient suspected of suffering from an autoimmune disease, including the steps of contacting human polymorphonuclear neutrophils able to release extracellular traps (NETs) with microspheres to produce NET-coated microspheres, contacting the NET-coated microspheres with the sample of bodily fluid, and labeling and subsequent analyzing of anti-neutrophil-cytoplasmic antibodies by flow cytometric methods.

Abstract: An analyte testing system for quantifying the presence of an analyte in a speciment by lateral flow chromatography. The system comprises a test cassette (10) with a lateral flow chromatography and a mobile hand-held processor device (16) comprising a digital camera (16a), a source of light (16b) and a processor (16c), which software and hardware (16c) are configured to determine automatically the distance between camera and object and the measures of light in the region of interest of the lateral flow chromatography prior any retrieval of image data for further analysis and quantification of the visual signals.

Abstract: A novel therapy concept based on a removal of circulating BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD) or highly at risk of developing arterial and vascular calcifications. The method comprises method of treatment of extracellular tissue and vascular calcifications, atherosclerosis, arteriosclerosis, and arterial calcification. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients as well as in animal models.

Abstract: Test kit, composition and a method of measuring vitamin D and its metabolites in a sample of bodily fluid from a subject, which sample contains vitamin D binding protein (DBP), comprising the steps of contacting said sample with megalin and/or a soluble fragment thereof under binding conditions to form a ternary complex containing DBP, a vitamin D metabolite and megalin or a fragment thereof; determining the amount of DBP bound by megalin; and relating the amount of megalin-bound DBP to the effective status of vitamin D in the circulation of said subject.

Abstract: Method of determining the health risk for myocardial infartion inpatients subjected to coronary angiography or suspected having an increased cardio-vascular health risk, wherein the concentration of parathyroid hormone is determined in vitro in serum or plasma sample of said patient wherein that the serum or plasma sample is contacted with beads binding oxidized parathyroid hormone and correlating the determined level of parathyroid hormone to the risk for myocardial infarction.

Abstract: A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.

Abstract: A method comprising the steps of: (a) collecting a stool sample with the analyte and transferring a defined amount of stool sample into a prepared vessel having a sieve filter and a predetermined amount of extraction solution; (b) suspending and extracting the stool sample in the extraction solution so that the analyte goes into solution; (c) filtering the extraction solution through the sieve filter and transferring a defined amount of extraction solution to a cellulosic fibrous web having predetermined absorbency; (d) rapid drying of the extraction solution on the cellulose fibrous web at ambient temperature by the capillary action of the fibrous web, wherein the fibrous web with the sample extraction solution represents a storage and transport form stable over days and weeks, on which analyte and digestive enzymes are physically separated from each other; (e) collecting and extracting the analyte from the fibrous web in a predetermined amount of assay buffer; (f) separating the fibrous web from the assay b

Abstract: A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n=224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n=116; p=0.915).